Bain Capital Life Sciences Investors as of Sept. 30, 2020
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 22 positions in its portfolio as reported in the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Springworks Therapeutics (SWTX) | 32.4 | $347M | 7.3M | 47.67 | |
| Arcutis Biotherapeutics (ARQT) | 10.9 | $117M | 4.0M | 29.30 | |
| Annexon (ANNX) | 9.1 | $98M | 3.2M | 30.23 | |
| Dicerna Pharmaceuticals | 6.8 | $73M | 4.1M | 17.99 | |
| Mersana Therapeutics (MRSN) | 6.0 | $64M | 3.4M | 18.62 | |
| Replimune Group (REPL) | 4.6 | $49M | 2.1M | 23.02 | |
| Dynavax Technologies (DVAX) | 4.4 | $47M | 11M | 4.32 | |
| Nurix Therapeutics (NRIX) | 4.2 | $45M | 1.3M | 34.91 | |
| Sage Therapeutics (SAGE) | 2.8 | $31M | 499k | 61.12 | |
| Constellation Pharmceticls I | 2.6 | $28M | 1.4M | 20.26 | |
| Kymera Therapeutics (KYMR) | 2.2 | $24M | 730k | 32.31 | |
| Savara (SVRA) | 2.1 | $23M | 5.1M | 4.48 | |
| Aeglea Biotherapeutics | 1.8 | $19M | 2.7M | 7.09 | |
| Aptinyx | 1.8 | $19M | 5.6M | 3.38 | |
| Marinus Pharmaceuticals | 1.7 | $18M | 1.4M | 12.85 | |
| Crinetics Pharmaceuticals In (CRNX) | 1.6 | $17M | 1.1M | 15.67 | |
| Therapeutics Acquisition Cor Com Cl A | 1.3 | $14M | 1.0M | 14.38 | |
| X4 Pharmaceuticals (XFOR) | 1.0 | $11M | 1.6M | 6.77 | |
| Arya Sciences Acquisition Corp Iii Com Cl A | 1.0 | $11M | 1.0M | 10.81 | |
| Solid Biosciences | 0.7 | $7.9M | 3.9M | 2.03 | |
| Bctg Acquisition Corp | 0.5 | $5.2M | 500k | 10.36 | |
| Panacea Acquisition Corp Unit 99/99/9999 | 0.5 | $5.0M | 500k | 10.00 |
